Xavier Forns1, Stuart C Gordon2, Eli Zuckerman3, Eric Lawitz4, Jose L Calleja5, Harald Hofer6, Christopher Gilbert7, John Palcza7, Anita Y M Howe7, Mark J DiNubile7, Michael N Robertson7, Janice Wahl7, Eliav Barr7, Maria Buti8. 1. Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain. Electronic address: xforns@clinic.ub.es. 2. Henry Ford Health System, Detroit, MI, USA. 3. Carmel Medical Center, Haifa, Israel. 4. The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA. 5. Servicio de Gastroenterología y Hepatología, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, Madrid, Spain. 6. Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. 7. Merck and Co., Inc., Kenilworth, NJ, USA. 8. Hospital Universitario Valle Hebron and Ciberehd, Barcelona, Spain.
Abstract
BACKGROUND & AIMS: The Phase-2 C-SALVAGE study evaluated an investigational interferon-free combination of grazoprevir (a NS3/4A protease inhibitor) and elbasvir (a NS5A inhibitor) with ribavirin for patients with chronic HCV genotype-1 infection who had failed licensed DAA-containing therapy. METHODS: C-SALVAGE was an open-label study of grazoprevir 100 mg and elbasvir 50 mg QD with weight-based ribavirin BID for 12 weeks in cirrhotic and non-cirrhotic patients with chronic HCV genotype-1 infection who had not attained SVR after ⩾4 weeks of peginterferon and ribavirin plus either boceprevir, telaprevir, or simeprevir. Exclusion criteria included decompensated liver disease, hepatocellular carcinoma, and HIV or HBV co-infection. The primary efficacy outcome was SVR12 defined as a HCV RNA level below the assay limit of quantification 12 weeks after the end of treatment. RESULTS: Of the 79 patients treated with ⩾1 dose of study drug, 66 (84%) patients had a history of virologic failure on a regimen containing a NS3/4A protease inhibitor; 12 of the other 13 patients discontinued prior treatment because of adverse experiences. At entry, 34 (43.6%) of 78 evaluable patients harbored NS3 RAVs. SVR12 rates were 76/79 (96.2%) overall, including 28/30 (93.3%) patients with genotype 1a infection, 63/66 (95.5%) patients with prior virologic failure, 43/43 (100%) patients without baseline RAVs, 31/34 (91.2%) patients with baseline NS3 RAVs, 6/8 (75.0%) patients with baseline NS5A RAVs, 4/6 (66.7%) patients with both baseline NS3 and RAVs, and 32/34 (94.1%) cirrhotic patients. None of the five reported serious adverse events were considered drug-related. CONCLUSIONS: Grazoprevir and elbasvir plus ribavirin for 12 weeks provides a promising new treatment option for patients after failure of triple therapy containing an earlier-generation protease inhibitor.
BACKGROUND & AIMS: The Phase-2 C-SALVAGE study evaluated an investigational interferon-free combination of grazoprevir (a NS3/4A protease inhibitor) and elbasvir (a NS5A inhibitor) with ribavirin for patients with chronic HCV genotype-1 infection who had failed licensed DAA-containing therapy. METHODS: C-SALVAGE was an open-label study of grazoprevir 100 mg and elbasvir 50 mg QD with weight-based ribavirin BID for 12 weeks in cirrhotic and non-cirrhotic patients with chronic HCV genotype-1 infection who had not attained SVR after ⩾4 weeks of peginterferon and ribavirin plus either boceprevir, telaprevir, or simeprevir. Exclusion criteria included decompensated liver disease, hepatocellular carcinoma, and HIV or HBV co-infection. The primary efficacy outcome was SVR12 defined as a HCV RNA level below the assay limit of quantification 12 weeks after the end of treatment. RESULTS: Of the 79 patients treated with ⩾1 dose of study drug, 66 (84%) patients had a history of virologic failure on a regimen containing a NS3/4A protease inhibitor; 12 of the other 13 patients discontinued prior treatment because of adverse experiences. At entry, 34 (43.6%) of 78 evaluable patients harbored NS3 RAVs. SVR12 rates were 76/79 (96.2%) overall, including 28/30 (93.3%) patients with genotype 1a infection, 63/66 (95.5%) patients with prior virologic failure, 43/43 (100%) patients without baseline RAVs, 31/34 (91.2%) patients with baseline NS3 RAVs, 6/8 (75.0%) patients with baseline NS5A RAVs, 4/6 (66.7%) patients with both baseline NS3 and RAVs, and 32/34 (94.1%) cirrhotic patients. None of the five reported serious adverse events were considered drug-related. CONCLUSIONS: Grazoprevir and elbasvir plus ribavirin for 12 weeks provides a promising new treatment option for patients after failure of triple therapy containing an earlier-generation protease inhibitor.
Authors: Mark S Sulkowski; Walford J Fessel; Adriano Lazzarin; Juan Berenguer; Natalia Zakharova; Hugo Cheinquer; Pierre Côté; Douglas Dieterich; Adrian Gadano; Gail Matthews; Jean-Michel Molina; Christophe Moreno; Juan Antonio Pineda; Federico Pulido; Antonio Rivero; Jurgen Rockstroh; Dennis Hernandez; Fiona McPhee; Timothy Eley; Zhaohui Liu; Patricia Mendez; Eric Hughes; Stephanie Noviello; Peter Ackerman Journal: Hepatol Int Date: 2017-02-16 Impact factor: 6.047
Authors: Sarita D Boyd; LaRee Tracy; Takashi E Komatsu; Patrick R Harrington; Prabha Viswanathan; Jeff Murray; Adam Sherwat Journal: Clin Drug Investig Date: 2017-04 Impact factor: 2.859
Authors: Massimo Andreoni; Sergio Babudieri; Savino Bruno; Massimo Colombo; Anna L Zignego; Vito Di Marco; Giovanni Di Perri; Carlo F Perno; Massimo Puoti; Gloria Taliani; Erica Villa; Antonio Craxì Journal: Infection Date: 2017-11-02 Impact factor: 3.553